Page 129 - Read Online

Ding et al. Hepatoma Res 2019;5:10 I http://dx.doi.org/10.20517/2394-5079.2018.115 Page 7 of 8

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010;58:258-66.
2. Chan SL, Wong VW, Qin S, Chan HL. Infection and cancer: the case of hepatitis B. J Clin Oncol 2016;34:83-90.
3. Chinese Society of Hepatology, Chinese Society of Infectious Diseases; Chinese Medical Association; Hou JL, Wei L. The guideline
of prevention and treatment forchronic hepatitis B: a 2015 update. Chin J Hepato (Zhonghua GanZang Bing Za Zhi) 2015;23: 888-
905. (in Chinese)
4. Quasdorff M, Protzer U. Control of hepatitis B virus at the level of transcription. J Viral Hepat 2010;17:527-36.
5. Stahl M, Beck J, Nassal M. Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the
terminal protein domain that contributes to epsilon RNA binding. J Virol 2007;81:13354-64.
6. Wang J, Yu Y, Li G, Shen C, Meng Z, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic
activity markers in entecavir-treated patients. J Hepatol 2018;68:16-24.
7. Halgand B, Desterke C, Rivière L, Fallot G, Sebagh M, et al. Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: a
nosological and prognostic determinant. Hepatology 2018;67:86-96.
8. Wang J, Shen T, Huang X, Kumar GR, Chen X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be
associated with persistence of viral infection and rebound. J Hepatol 2016;65:700-10.
9. Hong X, Kim ES, Guo H. Epigenetic regulation of hepatitis B virus covalently closed circular DNA: implications for epigenetic
therapy against chronic hepatitis B. Hepatology 2017;66:2066-77.
10. Block TM, Guo H, Guo JT. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis 2007;11:685-706.
11. Jones SA, Hu J. Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention.
Emerg Microbes Infect 2013;2:e56.
12. Stahl M, Beck J, Nassal M. Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the
terminal protein domain that contributes to epsilon RNA binding. J Virol 2007;81:13354-64.
13. Prange R. Host factors involved in hepatitis B virus maturation, assembly, and egress. Med Microbiol Immunol 2012;201:449-61.
14. Wang S, Qiu L, Yan X, Jin W, Wang Y, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus
replication through cyclin G(1) -modulated P53 activity. Hepatology 2012;55:730-41.
15. Deng M, Hou J, Hu J, Wang S, Chen M, et al. Hepatitis B virus mRNAs functionally sequester let-7a and enhance hepatocellular
carcinoma. Cancer Lett 2016; 383:62-72.
16. Li C, Wang Y, Wang S, Wu B, Hao J, et al. Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein,
which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol 2013;87: 2193-205.
17. Wang Y, Jiang L, Ji X, Yang B, Zhang Y, et al. Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor
microRNA miR-15a/miR-16-1 in hepatocytes. J Biol Chem 2013;288:18484-93.
18. Yang X, Li H, Sun H, Fan H, Hu Y, et al. Hepatitis B virus-encoded microRNA controls viral replication. J Virol 2017;91:01919-16.
19. Yin S, Fan Y, Zhang H, Zhao Z, Hao Y, et al. Differential TGF-β pathway targeting by miR-122 in humans and mice affects liver
cancer metastasis. Nat Commun 2016;7:11012.
20. Sato S, Li K, Kameyama T, Hayashi T, Ishida Y, et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral
factor for hepatitis B virus. Immunity 2015,42:123-32.
21. Breitkreutz R, Zhang W, Lee M, Hoffmann A, Tokus M, et al. Hepatitis B virus nucleic acids circulating in the blood: distinct patterns
in HBs carriers with hepatocellular carcinoma. Ann N Y Acad Sci 2001;945:195-206.
22. Hilger C, Velhagen I, Zentgraf H, Schroder CH. Diversity of hepatitis B virus X gene-related transcripts in hepatocellular carcinoma:
a novel polyadenylation site on viral DNA. J Virol 1991;65:4284-91.
23. Takata A, Otsuka M, Ohno M, Kishikawa T, Yoshikawa T, et al. Mutual antagonism between hepatitis B viral mRNA and host
microRNA let-7. Sci Rep 2016;6:23237.
24. Giersch K, Allweiss L, Volz T, Dandri M, Lutgehetmann M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol
2017;66:460-2.
25. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a
2015 update. Hepatol Int 2016;10:1-98.
26. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, et al; European Association for the Study of the Liver. EASL 2017 clinical
practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.
27. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, et al; American Association for the Study of Liver Diseases. AASLD
guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-83.
28. Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, et al. Hepatitis B virus pregenomic RNA is present in virions in